Posted On: 12/03/2015 5:12:04 PM
Post# of 145138
$RGBP FDA Approval on Horizon; Scientific advisory board(link below): http://www.regenbiopharmainc.com/scientific-a...board.html
Due some extensive DD on this one, people. We have not one, but two FDA approvals in the works. The first is Hemaxellerate for aplastic anemia. It has shown no toxicity at ten times the therapeutic dose. FDA requested a Good Laboratory practices study to confirm. Charles River Labs, the GLP facility confirmed the findings as accurate. The second approval in the works is for dCellvax, an onco-immuno-therapeutic vaccine. This one has the Bristol Myers Squibb name next to it. See the dCellVax logo underscored by the Bristol logo below here: http://www.regenbiopharmainc.com/product-pipeline.html Now read this PR about the RGBP/Bristol Myers relationship: http://www.marketwired.com/press-release/rege...994367.htm
And for some speculative icing on the cake. See this next quote I have extracted from the PR linked to it below.
Bristol-Myers and AbbVie Inc co-developed the drug, but Empliciti will be sold only by Bristol-Myers.
"The company is considered the leader among drugmakers racing to develop a new wave of cancer treatments that harness the immune system, including its recently approved immuno-oncology product Opdivo."
http://news.yahoo.com/fda-approves-bristol-my...nance.html
Why is that quote isolated? Read it again and pay attention to these words: leader, racing, develop, immuno-oncology. That's right; they want RGBP's IP so they can keep their edge.
Due some extensive DD on this one, people. We have not one, but two FDA approvals in the works. The first is Hemaxellerate for aplastic anemia. It has shown no toxicity at ten times the therapeutic dose. FDA requested a Good Laboratory practices study to confirm. Charles River Labs, the GLP facility confirmed the findings as accurate. The second approval in the works is for dCellvax, an onco-immuno-therapeutic vaccine. This one has the Bristol Myers Squibb name next to it. See the dCellVax logo underscored by the Bristol logo below here: http://www.regenbiopharmainc.com/product-pipeline.html Now read this PR about the RGBP/Bristol Myers relationship: http://www.marketwired.com/press-release/rege...994367.htm
And for some speculative icing on the cake. See this next quote I have extracted from the PR linked to it below.
Bristol-Myers and AbbVie Inc co-developed the drug, but Empliciti will be sold only by Bristol-Myers.
"The company is considered the leader among drugmakers racing to develop a new wave of cancer treatments that harness the immune system, including its recently approved immuno-oncology product Opdivo."
http://news.yahoo.com/fda-approves-bristol-my...nance.html
Why is that quote isolated? Read it again and pay attention to these words: leader, racing, develop, immuno-oncology. That's right; they want RGBP's IP so they can keep their edge.
(0)
(0)
Do your own DD. Assume everyone here is either an amateur trader/investor or a paid interest such as a compensated pumper/basher. My posts are strictly for entertainment purposes. I am not on Wall St., do not work for a group, and only get paid when my personal investments materialize. I am only responsible for my own gains and losses; no one is to blame for my mistakes or for any advice taken from postings; likewise, I am not to blame for any advice you take of mine, regardless of gains or losses from doing so. Good luck to all; may you live long and prosper greatly.
